Halistatins 1, 2 & 3
Jack Geltosky, PhD
Senior Vice President of Business Development, Life Sciences
Arizona Technology Enterprises, LLC (AzTE)
George Pettit, PhD
Department of Chemistry and Biochemistry
Arizona State University
Halistatins 1, 2 and 3
AzTE Cases # 626, 627, 701
Intellectual Property Status:
U.S. Patent 5,426,194
U.S. Patent 5,352,804
U.S. Patent 5,519,050
Halistatins are highly potent polyether macrolides with anti-mitotic actions that were originally isolated from certain marine sponges. Similar polyether macrolides, such as, Bryostatin 1 (Ph2), Halichondrin B (PC) and its analog, E7389 (Ph 2), are being tested both preclinically and clinically as anti-cancer agents.
Halistatin 1 has highly potent cytotoxic activity in vitro against P388 cells (ED50 of 4x10-4 μg/mL) and against 60 human cancer cell lines from the NCI’s anti-tumor screening panel (average overall panel GI50 of 7x10-10 M).
Halistatin 2 has highly potent cytotoxic activity in vitro against P388 cells (ED50 of 4x10-4 μg/mL) and against 60 human cancer cell lines from the NCI’s anti-tumor screening panel (average overall panel GI50 of 7x10-10 M).
Halistatin 3 strongly inhibits growth (ED50 of 3.5x10-5 μg/mL) of P388 leukemia cells and a ‘mini’ panel of human cancer cell lines (GI50, μg/mL): brain (SF-295, 3.5x10-5), lung (NCI-460, 2.5x10-5), colon (KM 2062, 5.1x10-6), ovary (OVCAR-3, 1.3x10-5), renal (A498, 5.6x10-5) and melanoma (SK-MEL-5, 2.5x10-5).
These novel compounds have applications as:
- Anti-cancer therapeutic agents
Benefits and Advantages
- Diversity – The new compounds are structural analogs of confirmed very potent candidates for anti-cancer drugs.
- Efficacy – The new compounds also possess promising anti-mitotic activities.